$1.70
1.19% today
Nasdaq, Jun 27, 05:16 pm CET
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Lexicon Pharmaceuticals, Inc. Share price

$1.68
+0.06 3.70% 1M
+0.27 19.15% 6M
+0.15 9.80% YTD
-0.49 22.58% 1Y
-3.84 69.57% 3Y
-4.01 70.47% 5Y
-9.45 84.91% 10Y
Nasdaq, Closing price Wed, Jun 26 2024
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Key figures

Market capitalization $607.31m
Enterprise Value $357.97m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 154.97
P/S ratio (TTM) P/S ratio 262.90
P/B ratio (TTM) P/B ratio 1.43
Sales growth (TTM) Sales growth 1,734.13%
Turnover (TTM) Turnover $2.31m
EBIT (operating result TTM) EBIT $-185.94m
Free cash flow (TTM) Free cash flow $-185.64m
Cash position $355.60m
EPS (TTM) EPS $-0.82
P/E ratio expected negative
P/S ratio expected 21.72
EV/Sales expected 12.80
Short interest 14.28%
Show more

Is Lexicon Pharmaceuticals, Inc. a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,947 shares worldwide.

Lexicon Pharmaceuticals, Inc. Share analysis

Unlock scores for free

Analyst opinions

6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

4x Buy
67%
2x Hold
33%

Analyst opinions

6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Lexicon Pharmaceuticals, Inc.

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
2.31 2.31
1,677% 1,677%
100%
- Direct costs 0.70 0.70
63% 63%
30%
1.61 1.61
637% 637%
70%
- Selling and administrative expenses 126 126
117% 117%
5,468%
- Research and development costs 61 61
23% 23%
2,626%
-185 -185
71% 71%
-8,024%
- Depreciation and amortization 0.59 0.59
37% 37%
26%
EBIT (operating result) EBIT -186 -186
71% 71%
-8,049%
Net profit -192 -192
74% 74%
-8,315%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Lexicon Pharmaceuticals, Inc. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Lexicon Pharmaceuticals, Inc. Share News

Neutral
GlobeNewsWire
6 days ago
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease
Neutral
GlobeNewsWire
8 days ago
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP)
Neutral
GlobeNewsWire
13 days ago
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange County Convention Center in Orlando, Florida.
More Lexicon Pharmaceuticals, Inc. News

Company profile

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Head office United States
CEO Lonnel Coats
Employees 285
Founded 1995
Website www.lexpharma.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now